Using hyperpolarized 129-Xenon MRI to monitor lung disease
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease
This study is testing a new type of MRI using hyperpolarized xenon to see if it can better track lung problems in people with fibrosing interstitial lung disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus) |
| Trial ID | NCT05914506 on ClinicalTrials.gov |
What this trial studies
This project investigates the use of non-invasive imaging techniques to detect and track early signs of pulmonary fibrosis and related heart issues in patients with fibrosing interstitial lung disease. The study aims to evaluate baseline risk factors that may influence disease progression and responses to anti-fibrotic treatments. By employing hyperpolarized xenon-129 MRI, researchers hope to provide a more accurate assessment of lung function compared to traditional imaging methods. The study will include patients diagnosed with idiopathic pulmonary fibrosis or other fibrotic interstitial lung diseases who meet specific criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-90 diagnosed with idiopathic pulmonary fibrosis or fibrotic interstitial lung disease who are prescribed anti-fibrotic treatment.
Not a fit: Patients with contraindications for MRI or those with overlapping emphysemic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for patients with fibrosing interstitial lung disease.
How similar studies have performed: While the use of hyperpolarized xenon MRI is a novel approach, similar imaging techniques have shown promise in other studies for assessing lung conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed signed consent * Age 18-90 * Pre-menopausal women must be confirmed non-pregnant by an onsite test. * Patients diagnosed with IPF or fibrotic ILD who fulfills PPF criteria, and are prescribed antifibrotic treatment. * Cognitively able to understand and participate in the study Exclusion Criteria: * Contraindications for MRI: * Pacemaker, neurostimulator or cochlear implant * Metal foreign bodies such as fragments and irremovable piercings * Unsafe medical implants (safety of heart valves, hips and the like must be confirmed) * Intrathoracic clips or coils * Cardiac pacemakers * Claustrophobia * Largest circumference including arms \> 160 cm * Contraindications to gadolinium contrast * eGFR \< 30 mL/min/1.73m2 * Previous adverse reactions to gadolinium * Overlapping emphysemic disease where the emphysema-component outweighs the fibrosis * Unable to perform breath-hold of minimum 20 seconds. * Allergy to Xenon * Breast feeding * Evidence of ongoing respiratory infections at time of MR examinations
Where this trial is running
Aarhus
- Aarhus University, Department of Clinical Medicine, MR Research Centre — Aarhus, Denmark (Recruiting)
Study contacts
- Principal investigator: Elisabeth Bendstrup, Professor — Aarhus University Hospital
- Study coordinator: Mattias H. Kristensen, MD
- Email: mattias.kristensen@clin.au.dk
- Phone: +4525216724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.